Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
NGT HealthCare II (NGT) is an early-stage venture capital fund based in Nazareth, Israel, specializing in medical devices and life sciences. Founded to invest in promising technologies, NGT benefits from non-dilutive leverage provided by Israel’s Innovation Authority. The fund maintains strong ties with leading universities and research institutions, facilitating a steady flow of investment opportunities.
NGT invests in early-stage medical device and life sciences technologies, with a check size typically in the pre-seed to seed stages. The fund emphasizes social impact while delivering financial returns, actively supporting Arab entrepreneurs and promoting inclusion within Israel's medical startup ecosystem. NGT aims to stimulate economic growth in the Northern periphery of Israel.
NGT's portfolio includes notable companies such as: Prolor Biotech, sold to OPKO for $480 million; Mazor Robotics, sold to Medtronic for $1.6 billion; ReWalk, listed on NASDAQ (RWLK); and Corindus, sold to Siemens for $1.1 billion.
Submit your pitch through their form at ngt-healthcare2.com or email info@ngt-healthcare2.com with your deck.
NGT typically participates in early-stage rounds and may lead investments depending on the opportunity and alignment with their focus areas.
NGT is open to follow-on investments, particularly in companies that demonstrate strong growth potential and alignment with their impact goals.
The specific size of NGT's current fund is not disclosed, but it focuses on early-stage investments in the medical device and life sciences sectors.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.